Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Tenax Therapeutics (TENX) Research & Development (2016 - 2017)

Tenax Therapeutics' Research & Development history spans 8 years, with the latest figure at $7.1 million for Q4 2017.

  • For Q4 2017, Research & Development fell 70.29% year-over-year to $7.1 million; the TTM value through Dec 2017 reached $3.5 million, down 82.01%, while the annual FY2025 figure was $32.7 million, 157.08% up from the prior year.
  • Research & Development for Q4 2017 was $7.1 million at Tenax Therapeutics, up from -$253973.0 in the prior quarter.
  • Across five years, Research & Development topped out at $23.7 million in Q4 2016 and bottomed at -$44.4 million in Q1 2013.
  • The 5-year median for Research & Development is $1.4 million (2014), against an average of -$1.6 million.
  • The largest annual shift saw Research & Development crashed 7503.88% in 2013 before it surged 89.2% in 2017.
  • A 5-year view of Research & Development shows it stood at -$44.4 million in 2013, then surged by 103.12% to $1.4 million in 2014, then skyrocketed by 74.67% to $2.4 million in 2015, then skyrocketed by 881.42% to $23.7 million in 2016, then plummeted by 70.29% to $7.1 million in 2017.
  • Per Business Quant, the three most recent readings for TENX's Research & Development are $7.1 million (Q4 2017), -$253973.0 (Q3 2017), and -$1.2 million (Q2 2017).